Warnings and Precautions: Gallbladder abnormalities may occur: Patients should be monitored periodically. Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be...
Dr Liu discusses his clinical experience prescribing and treating patients with Sandostatin® LAR Depot (octreotide acetate for injectable suspension).
See the proper mixing and administration of Sandostatin LAR Depot in this video.
Explore the history that led to the world’s first SSA* approved by the FDA for the severe diarrhea and flushing associated with metastatic carcinoid tumors. Take a look back at the years of research that led to the FDA approval of Sandostatin LAR Depot to reduce the severe diarrhea and flushing associated with metastatic carcinoid tumors.
FDA, US Food and Drug Administration; LAR, long-acting release; SSA, somatostatin analogue.
*Includes Sandostatin® (octreotide acetate) Immediate-release Injection and Sandostatin LAR Depot for all approved indications.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions:
Drug Interactions: The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Drugs mainly metabolized by CYP3A4 and which have a low therapeutic index should be used with caution.
Adverse Reactions: The most common adverse reactions occurring in patients receiving Sandostatin LAR Depot were biliary abnormalities (62%), injection site pain (20-50%), nausea (24-41%), abdominal pain (10-35%), fatigue (8-32%), headache (16-30%), hyperglycemia (27%), back pain (8-27%), constipation or vomiting (15-21%), dizziness (18-20%), sinus bradycardia (19%), pruritus (18%), URTI (10-18%), myalgia (4-18%), flatulence (9-16%), arthropathy (8-15%), rash (15%), generalized pain (4-15%), sinusitis (5-12%), conduction abnormalities (9%), hypoglycemia (4%), and arrhythmia (3%).
Please see full Prescribing Information.
Indication and Usage
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:
In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.